These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20492890)

  • 21. Etanercept in psoriasis.
    Papp KA
    Expert Opin Pharmacother; 2004 Oct; 5(10):2139-46. PubMed ID: 15461549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pustular psoriasis, palmoplantar psoriasis, erythodermal psoriasis and etanercept].
    López-Estebaranz JL; Ruiz-Genao D
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():35-9. PubMed ID: 20492878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Manifestation of Crohn's disease in a young woman during the course of treatment for severe form of chronic plaque psoriasis with etanercept.
    Tichy M; Hercogova J
    Dermatol Ther; 2014; 27(4):211-4. PubMed ID: 24548537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
    Sánchez-Regaña M; Dilmé E; Puig L; Bordas X; Carrascosa JM; Ferran M; Herranz P; García-Bustinduy M; López Estebaranz JL; Alsina M; Rodríguez MA; Ribera M; Fernández-López E; Moreno JC; Belinchón Romero I; Vidal D;
    Actas Dermosifiliogr; 2010 Mar; 101(2):156-63. PubMed ID: 20223158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
    Tan E; Baker C; Foley P
    Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.
    Liu SW; Velez NF; Lam C; Femia A; Granter SR; Townsend HB; Vleugels RA
    JAMA Dermatol; 2013 Oct; 149(10):1204-8. PubMed ID: 23986394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis.
    Sauder MB; Glassman SJ
    Int J Dermatol; 2013 May; 52(5):624-8. PubMed ID: 23489057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.
    Mocci G; Marzo M; Papa A; Armuzzi A; Guidi L
    J Crohns Colitis; 2013 Nov; 7(10):769-79. PubMed ID: 23453887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Off-label dermatologic uses of anti-TNF-a therapies.
    Alexis AF; Strober BE
    J Cutan Med Surg; 2005 Dec; 9(6):296-302. PubMed ID: 16699906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis.
    Saraceno R; Schipani C; Mazzotta A; Esposito M; Di Renzo L; De Lorenzo A; Chimenti S
    Pharmacol Res; 2008 Apr; 57(4):290-5. PubMed ID: 18400510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of etanercept in psoriasis: a critical review.
    Sánchez Carazo JL; Mahiques Santos L; Oliver Martinez V
    Drug Saf; 2006; 29(8):675-85. PubMed ID: 16872241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum.
    Carter JD; Gerard HC; Hudson AP
    Ann Rheum Dis; 2008 Aug; 67(8):1181-3. PubMed ID: 18299302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
    Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
    J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
    Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
    J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus.
    Wambier CG; Foss-Freitas MC; Paschoal RS; Tomazini MV; Simão JC; Foss MC; Foss NT
    J Am Acad Dermatol; 2009 May; 60(5):883-5. PubMed ID: 19389539
    [No Abstract]   [Full Text] [Related]  

  • 38. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.
    Kamarashev J; Lor P; Forster A; Heinzerling L; Burg G; Nestle FO
    Dermatology; 2002; 205(2):213-6. PubMed ID: 12218252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
    Mease PJ
    Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.